340bemployed.org

Your Free Source for 340B News and Commentary

  • Home
  • About Us
  • Employers
  • Job Seekers
  • Advertise
  • 340B Health

Bayer Limiting Distribution of Multiple Sclerosis Drug Betaseron

Customer's 340B status will not affect allotment, company says in letter
 

Print Article

February 20, 2014—Bayer HealthCare Pharmaceuticals has limited sales of its widely used, genetically engineered multiple sclerosis (MS) drug Betaseron due to inability to meet demand, effective with orders received on or after Jan. 1, the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) announced on its website today.[ms-protect-content id=”2799″]

Under HRSA policy, when a 340B covered outpatient drug is in short supply, its manufacturer must demonstrate that its allocation system treats 340B providers the same as non-340B providers. HRSA asks drugmakers to notify OPA at least four weeks in advance of altering its allocation procedures.

Betaseron (interferon beta-1b) was the first breakthrough treatment for MS symptoms. When it came on the market in 1993, demand was so extreme it was allocated to patients by lottery. It is the company’s top-selling drug globally, according to the company website.

Just this week, the newsletter Genetic Engineering & Biotechnology News reported that Betaseron was the fifth-best-selling MS drug in the U.S. last year, with $1.05 billion in sales. According to the Multiple Sclerosis Society website, only one other manufacturer is approved to market interferon beta-1b in the country (Novartis, under the brand name Extavia).

The letter from Bayer to OPA posted on the agency’s website does not explain the reasons for the shortage. “The risks imposed by anticipated unpredictability in demand are heightened by the critical role this drug plays in the lives of many patients with relapsing forms of MS,” the company wrote. “We anticipate that this limited distribution system will remain in place for the forseeable future and will best ensure that all patients of all providers have equal access to Betaseron.”

The company said it “will not require minimum purchase amounts per transaction, and importantly, a customer’s 340B participation status and the price a customer pays for Betaseron will not affect its quarterly allotment.”

Under the allocation system, Bayer will limit the number of Betaseron units available to each U.S. customer. The amount available to each customer will be limited to that customer’s average quarterly purchase volume in the third quarter of 2013 determined on a percentage basis and then applied to the current quarter’s available supply. New customers’ allocations will be based on similarly situated existing customer’s allocation percentages. Bayer will fill orders on a first-in, first-out basis, until a customer reaches its limit for the quarter, the company said.

Bayer limited the distribution of its second-highest-selling drug, the oral contraceptive Yaz, in 2007, 2008, and 2011, on occasions when it became subject to the 340B program’s “penny pricing” policy. [/ms-protect-content]

Follow us on X

340B Health Follow

340B Health is the leading advocate & resource for hospitals that serve their communities by participating in the 340B drug pricing program. #Protect340B

340BHealth
340bhealth 340B Health @340bhealth ·
18h

Medicare is proposing steeper non-drug payment reductions starting in 2026 for all hospitals paid under the OPPS and is planning a drug cost acquisition survey that could lead to more pay cuts for #340B hospitals as early as 2027.
We strongly oppose these proposals and will be…

Reply on Twitter 1948127138626027941 Retweet on Twitter 1948127138626027941 Like on Twitter 1948127138626027941 Twitter 1948127138626027941
340bhealth 340B Health @340bhealth ·
22 Jul

Nonprofit hospitals provide charity care services, serve as health care outposts in rural areas, invest in preventive care measures and social services, and more.

Their commitment to public health often goes unappreciated and they are criticized for their tax-exempt status. But…

Reply on Twitter 1947761725119332778 Retweet on Twitter 1947761725119332778 Like on Twitter 1947761725119332778 Twitter 1947761725119332778
340bhealth 340B Health @340bhealth ·
21 Jul

ICYMI: Provisions of the #IRA will require price caps on 10 drugs starting Jan. 1, 2026.
This list of drugs will grow in the future, and so might the financial impact for #340B covered entities.
We recently invited Meetali Desai, director of pharmacy services at @umassmemorial,…

Reply on Twitter 1947395155751014553 Retweet on Twitter 1947395155751014553 1 Like on Twitter 1947395155751014553 Twitter 1947395155751014553
Load More

RSS 340B Informed

  • An In-Depth Look at Total 340B Purchases
  • Ideas for 340B Changes Could Lead to Legislation
  • Help From 340B After a Rare Diagnosis and an Unaffordable Bill

Copyright © 2025 · 340B Health